Onconetix Faces Delisting Concerns

Ticker: ONCO · Form: 8-K · Filed: 2025-04-18T00:00:00.000Z

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

TL;DR

Onconetix might get delisted, check their listing status.

AI Summary

Onconetix, Inc. (formerly Blue Water Biotech, Inc.) filed an 8-K on April 18, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio, 45202.

Why It Matters

This filing indicates potential issues with Onconetix, Inc.'s continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's trading viability and investor confidence.

Key Players & Entities

FAQ

What specific listing rule or standard has Onconetix, Inc. failed to satisfy?

The filing does not specify the exact listing rule or standard that Onconetix, Inc. has failed to satisfy, only that a notice has been issued.

What is the exact date of the earliest event reported in this 8-K filing?

The earliest event reported is dated April 14, 2025.

What was Onconetix, Inc. previously known as?

Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.

Where are Onconetix, Inc.'s principal executive offices located?

The principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio, 45202.

What is the Commission File Number for Onconetix, Inc.?

The Commission File Number for Onconetix, Inc. is 001-41294.

From the Filing

0001213900-25-033295.txt : 20250418 0001213900-25-033295.hdr.sgml : 20250418 20250418143054 ACCESSION NUMBER: 0001213900-25-033295 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250414 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Other Events FILED AS OF DATE: 20250418 DATE AS OF CHANGE: 20250418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 25850152 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 8-K 1 ea0238654-8k_oncon.htm CURRENT REPORT false 0001782107 0001782107 2025-04-14 2025-04-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 14, 2025   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41294   83-2262816 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , Ohio   45202 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 513 ) 620-4101     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered Common Stock, par value $0.00001 per share   ONCO   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.   As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on January 24, 2025, Onconetix, Inc. (the “Company”) received a letter from the Listing

View on Read The Filing